TSE:9629
TSE:9629Software

PCA (TSE:9629) Margin Compression To 9% Challenges Bullish Profitability Narratives

PCA (TSE:9629) has released its Q3 2026 numbers, with revenue of ¥4,539 million and basic EPS of ¥23.24, setting the tone for how investors will weigh the latest move in profitability. The company has seen revenue range from ¥4,166 million in Q3 2025 to ¥4,539 million in Q3 2026, while quarterly EPS has moved between ¥14.86 and ¥26.43 over the same stretch. This provides a clearer view of how the top and bottom line have been tracking through recent periods. With trailing net profit margins...
TSE:7962
TSE:7962Commercial Services

King Jim (TSE:7962) Margin Improvement In Q2 2026 Tests Bearish Earnings Narratives

King Jim (TSE:7962) has put a stronger set of numbers on the table for Q2 2026, with revenue of ¥9.7b and basic EPS of ¥11.58 as net income reached ¥325.94m for the quarter. The company has seen quarterly revenue move around the ¥8.3b to ¥10.9b range over the past six reported periods, with basic EPS swinging from a loss of ¥10.63 in Q1 2026 to a profit of ¥11.58 in Q2 2026 after periods as low as a loss of ¥7.76 and as high as ¥16.49 since early 2025. This sets up a story where investors are...
TSE:4568
TSE:4568Pharmaceuticals

A Look At Daiichi Sankyo (TSE:4568) Valuation After ENHERTU’s Latest Oncology Approvals

Daiichi Sankyo Company (TSE:4568) is back in focus after China approved ENHERTU as the first HER2 directed antibody drug conjugate for second line HER2 positive metastatic gastric cancer. This development spotlights its oncology pipeline alongside recent European regulatory progress. See our latest analysis for Daiichi Sankyo Company. Despite the positive headlines around ENHERTU and recent corporate updates, Daiichi Sankyo Company's share price has had a weak patch, with a 30 day share price...